Cantargia confirms enrollment in Phase IIa trial for CAN04 monotherapy
Category: #health  | By Mateen Dalal  | Date: 2019-07-06 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Cantargia confirms enrollment in Phase IIa trial for CAN04 monotherapy

All the 20 patients for the monotherapy arm of the trial have begun treatment with 10 mg/kg dosage level

Swedish biotech firm Cantargia has reportedly announced full recruitment of CAN04 monotherapy arm in an existing Phase IIa clinical study in cancer patients.

Sources with knowledge on the matter informed that CAN04 (nidanilimab) is an antibody from Cantargia which is being investigated in a three-armed open label Phase IIa trial CANFOUR. Under this, CAN04 is evaluated as monotherapy or in chemotherapy combinations in pancreatic cancer (PDAC) or non-small cell lung cancer (NSCLC) patients.

All the 20 patients for the monotherapy arm of the trial have begun treatment with 10 mg/kg dose. The Safety, overall, has been in line with Phase I results. Outcome of the monotherapy, including efficacy and biomarkers are expected to be ready during fourth quarter of 2019, the sources informed.

Cantargia, on the basis of fast recruitment and good safety, is planning to utilize this opportunity to add more patients for generating safety and biomarker data at higher dosage level. Enrollment for the combination arms is also ongoing parallel to the monotherapy arm.

Sources stated that tumor biopsies have been obtained from most for the patients in the study, which were taken before and after therapy. Analyzing these biopsies will provide insights into the impact of CAN04 in the tumor microenvironment. Biomarkers would also be analyzed in the serum and the outcomes of these analyses are expected together with the efficacy results from CT-sans, sources added.

For the uninitiated, Cantargia develops pharmaceuticals based on antibodies against the interleukin 1 receptor accessory protein, or IL1RAP. IL1RAP with high functions and affinity is bound by antibody CAN04 through blockade of interleukin 1 signaling as well as ADCC. Apparently, almost 70% of PDAC patients and 80% of NSCLC patients overexpress IL1RAP on cancer cells, while in these diseases every patient has cells containing IL1RAP in the tumor microenvironment.

Source Credits: https://cantargia.com/en/press-releases/cantargia-announce-full-recruitment-of-can04-monotherapy-arm-in-ongoing-phase-iia-clinical-trial

 

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Russia-Ukraine war puts UK fish & chips industry in severe jeopardy

Russia-Ukraine war puts UK fish & chips industry in severe jeopardy

By Mateen Dalal

The on-going conflict between Russia and Ukraine has adversely affected the fish and chips industry in the United Kingdom, driving the closure of centuries-old shops, sharp price hikes, and change in menus. The National Federation of Fish Friers (...

U.S Govt. pledges $3.16 bn funding to boost EV battery manufacturing

U.S Govt. pledges $3.16 bn funding to boost EV battery manufacturing

By Mateen Dalal

The U.S. Department of Energy (DOE) has reportedly announced funds of $3.16 billion from President Joe Biden’s ‘Bipartisan Infrastructure Law’ for bolstering the domestic battery manufacturing and supply chain and creating more jobs...

Ammann rolls out new ADS technology to analyze jobsite compaction data

Ammann rolls out new ADS technology to analyze jobsite compaction data

By Mateen Dalal

Swiss mechanical engineering company Ammann has reportedly introduced a new ADS (Ammann Documentation System) technology. This new technology is geared towards capturing and further analyzing jobsite compaction data, which can lead to improved qualit...